323 related articles for article (PubMed ID: 17195205)
1. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
Grube E; Buellesfeld L
Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
[TBL] [Abstract][Full Text] [Related]
3. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
[TBL] [Abstract][Full Text] [Related]
4. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?
Buellesfeld L; Grube E
Herz; 2004 Mar; 29(2):167-70. PubMed ID: 15054589
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement.
Neumann FJ; Desmet W; Grube E; Brachmann J; Presbitero P; Rubartelli P; Mügge A; Di Pede F; Füllgraf D; Aengevaeren W; Spedicato L; Popma JJ
Circulation; 2005 Apr; 111(16):2107-11. PubMed ID: 15851617
[TBL] [Abstract][Full Text] [Related]
6. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up.
Rensing BJ; Vos J; Smits PC; Foley DP; van den Brand MJ; van der Giessen WJ; de Feijter PJ; Serruys PW
Eur Heart J; 2001 Nov; 22(22):2125-30. PubMed ID: 11686669
[TBL] [Abstract][Full Text] [Related]
7. Drug-eluting stents: clinical experiences and perspectives.
Grube E; Gerckens U; Buellesfeld L
Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
[TBL] [Abstract][Full Text] [Related]
8. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
Hausleiter J; Kastrati A; Wessely R; Dibra A; Mehilli J; Schratzenstaller T; Graf I; Renke-Gluszko M; Behnisch B; Dirschinger J; Wintermantel E; Schömig A;
Eur Heart J; 2005 Aug; 26(15):1475-81. PubMed ID: 15975990
[TBL] [Abstract][Full Text] [Related]
9. Everolimus for stent-based intracoronary applications.
Grube E; Buellesfeld L
Rev Cardiovasc Med; 2004; 5 Suppl 2():S3-8. PubMed ID: 15184828
[TBL] [Abstract][Full Text] [Related]
10. Procedural and long-term results of sirolimus-eluting stent in patients at high risk for restenosis.
Presbitero P; Zavalloni D; Scatturin M; Marisco F; Pagnotta P; Boccuzzi G
Minerva Cardioangiol; 2004 Jun; 52(3):189-94. PubMed ID: 15194980
[TBL] [Abstract][Full Text] [Related]
11. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
Silber S
J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
[TBL] [Abstract][Full Text] [Related]
13. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease.
Störger H; Grube E; Hofmann M; Schwarz F; Haase J
J Interv Cardiol; 2004 Dec; 17(6):387-90. PubMed ID: 15546290
[TBL] [Abstract][Full Text] [Related]
14. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
[TBL] [Abstract][Full Text] [Related]
15. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
[TBL] [Abstract][Full Text] [Related]
16. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model.
Collingwood R; Gibson L; Sedlik S; Virmani R; Carter AJ
Catheter Cardiovasc Interv; 2005 Jun; 65(2):227-32. PubMed ID: 15900559
[TBL] [Abstract][Full Text] [Related]
17. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
[TBL] [Abstract][Full Text] [Related]
18. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent.
Tanabe K; Degertekin M; Regar E; Ligthart JM; van der Giessen WJ; Serruys PW
Catheter Cardiovasc Interv; 2002 Sep; 57(1):65-8. PubMed ID: 12203931
[TBL] [Abstract][Full Text] [Related]
19. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
Perin EC
Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
[TBL] [Abstract][Full Text] [Related]
20. [When are drug-eluting stents effective? A critical analysis of the presently available data].
Silber S
Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
